Research Article
Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease
Table 6
Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with both concomitant use of immunomodulators and penetrating disease.
| ||||||||||||||||||||||||||||||||
Factors were statistically analyzed by Fisher’s exact test. IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval. |